While MaxCyte Inc has underperformed by -7.83%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MXCT fell by -63.22%, with highs and lows ranging from $5.20 to $1.26, whereas the simple moving average fell by -45.76% in the last 200 days.
On August 11, 2025, BTIG Research Downgraded MaxCyte Inc (NASDAQ: MXCT) to Neutral. A report published by William Blair on August 07, 2025, Downgraded its rating to ‘Mkt Perform’ for MXCT. Stephens also rated MXCT shares as ‘Overweight’, setting a target price of $6 on the company’s shares in an initiating report dated July 22, 2025. Craig Hallum Initiated an Buy rating on November 29, 2023, and assigned a price target of $7. Cowen initiated its ‘Outperform’ rating for MXCT, as published in its report on October 15, 2021. Wedbush also rated the stock as ‘Outperform’.
Analysis of MaxCyte Inc (MXCT)
Further, the quarter-over-quarter decrease in sales is -18.43%, showing a negative trend in the upcoming months.
To gain a thorough understanding of MaxCyte Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -21.73% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 11.71, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and MXCT is recording an average volume of 825.55K. On a monthly basis, the volatility of the stock is set at 5.61%, whereas on a weekly basis, it is put at 8.94%, with a loss of -5.56% over the past seven days. Furthermore, long-term investors anticipate a median target price of $6.68, showing growth from the present price of $1.53, which can serve as yet another indication of whether MXCT is worth investing in or should be passed over.
How Do You Analyze MaxCyte Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 8.45%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 68.37% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
